CEO Executive AssistantLaunch excellence in the pharmaceutical industry is a multifunctional achievement. It requires regulatory precision, commercial readiness, medical affairs preparation, supply chain reliability, market access execution, and external communications working in coordinated fashion over a multi-year development period. No CEO can personally oversee all of these dimensions without disrupting the very execution they are trying to ensure.
The paradox of pharma launch management is that CEO over-involvement in launch operations often causes the problems it is intended to prevent: commercial teams that defer to the CEO rather than making tactical decisions in real time, regulatory affairs professionals who hedge their recommendations based on what they think the CEO wants to hear, and cross-functional coordination that stalls waiting for CEO resolution of questions that functional leaders should resolve among themselves.
This guide establishes a delegation framework for pharma launch excellence that channels CEO engagement into the moments and decisions that genuinely require executive involvement while building the cross-functional launch machine that executes independently and effectively.
The Launch Excellence Framework: Five Domains
Launch excellence requires delegation clarity across five functional domains:
Regulatory: Ensuring the approval pathway is managed effectively, label negotiations are optimized, and the approval itself is managed as a communications event. The Head of Regulatory Affairs or Chief Regulatory Officer owns this domain.
Medical: Preparing the medical community for the new therapy, including KOL development, publication strategy, medical education, and medical information readiness. The Chief Medical Officer or Head of Medical Affairs owns this domain.
Commercial: Building and executing the commercial launch plan, including brand strategy, sales force deployment, promotional development, and sales force training. The Chief Commercial Officer owns this domain.
Market Access: Securing formulary access and favorable reimbursement, including payer strategy, HEOR evidence development, and national and regional account management. The Head of Market Access (typically reporting to the CCO) owns this domain.
Supply Chain: Ensuring product is available for launch in required quantities and configurations, with appropriate inventory strategy. The Head of Supply Chain owns this domain.
The CEO’s role is to ensure each of these domains is appropriately led, adequately resourced, and effectively coordinated. The CEO is the coordinator-in-chief of the launch system, not the operator of any specific domain.
Establishing the Launch Governance Structure
Pharma launch excellence depends on clear governance that defines who makes which decisions at what level and how cross-functional issues are resolved. The governance structure should be established two to three years before anticipated approval.
Launch Steering Committee (LSC): Chaired by the CCO, with all domain owners (CMO, Head of Regulatory, Head of Market Access, Head of Supply Chain) as members. Meets monthly during late-stage development, weekly in the 12 months around approval. Makes all cross-functional launch decisions within the approved launch strategy and investment.
Executive Sponsor (CEO): Reviews LSC progress quarterly through a structured readout, approves major investment decisions, and resolves any issues that cannot be resolved within the LSC. The CEO is not a regular LSC attendee.
Board Oversight: The CEO presents launch readiness status to the board at each board meeting in the 18 months around anticipated approval. The board does not manage launch execution.
This governance structure gives the commercial team clear authority and accountability while ensuring the CEO remains appropriately informed and involved at strategic decision points.
Delegating Pre-Launch Market Preparation
The 18 to 24 months before anticipated approval are when market preparation work is most intensive. This pre-launch period includes: KOL development by Medical Affairs, early payer engagement by Market Access, competitive positioning development by Commercial, and regulatory label strategy work by Regulatory Affairs.
All of this pre-launch work should be organized and led by the respective domain owners within the LSC governance structure. The CEO’s pre-launch activities should be limited to: a small number of high-visibility meetings with key payer decision-makers or KOLs where CEO presence adds credibility (organized by Medical Affairs and Market Access), investor communications about the anticipated launch (coordinated by IR), and trade association or policy engagement on access issues related to the launch indication.
The CEO who is attending every pre-launch KOL advisory board, reviewing every payer submission, and editing every promotional concept is operating at the wrong organizational level. These activities are well within the competence of the domain experts who own them.
The CEO’s Launch Day Role
Launch day, meaning the day of FDA approval or the commercial launch date, is a significant organizational moment where CEO visibility matters. Define the CEO’s launch day role explicitly:
- Lead the all-staff communication announcing the approval
- Conduct the investor and media communications (press release delivery, investor call if applicable)
- Personal outreach to the company’s most important external stakeholders
- Be available for employee engagement through the day
The logistics of launch day communications should be prepared by the Head of IR, the PR team, and the Head of Communications, with the CCO coordinating the commercial aspects. The CEO delivers and connects; the supporting teams prepare and manage.
For a broader framework on how launch delegation fits within the overall commercial operations delegation structure, see pharma CEO delegation guide, which covers how pharma CEOs can maintain strategic direction across commercial and R&D functions simultaneously.
Managing Launch Performance Shortfalls
Even with excellent preparation, launches do not always meet their initial forecasts. How the CEO responds to launch underperformance is a critical delegation test.
The natural but counterproductive response is to increase CEO involvement in commercial operations when performance is disappointing. This typically makes the situation worse: commercial teams lose confidence in their own judgment, decision-making slows as teams wait for CEO approval, and the tactical flexibility that the CCO needs to respond to market conditions is replaced by executive-level oversight of day-to-day commercial decisions.
The correct response to launch underperformance is: the CEO supports the CCO in conducting a rigorous diagnosis of what is driving the shortfall, approves any significant resource reallocation required for the commercial response, communicates with investors about the performance challenge and the response plan, and then returns to a strategic oversight role while the CCO executes the recovery.
This requires the CEO to trust the CCO’s commercial judgment even in difficult circumstances. That trust should be calibrated on the quality of the CCO’s diagnosis and response plan, not withheld because performance is off track.
Cross-Functional Launch Coordination
Many launch failures are coordination failures: Market Access gets formulary access later than expected, supply chain underestimates demand in the launch quarter, or Medical Affairs and Commercial alignment on messaging breaks down. The LSC governance structure is designed to prevent these failures by creating a regular forum for cross-functional alignment.
The CEO’s role in cross-functional launch coordination is to ensure the governance structure is working, not to be the coordinator personally. If the LSC is resolving cross-functional issues effectively, the CEO hears about resolved issues in the monthly steering committee readout. If issues are escalating to the CEO for resolution, it signals that either the governance structure is not working or that the issue genuinely requires executive judgment to resolve.
Escalations to the CEO should be exceptional. When they occur, the CEO makes the decision quickly and clearly, rather than holding the decision while seeking more information or consultation. Slow escalation resolution is as damaging to launch execution as no escalation structure at all.
Delegating Post-Launch Lifecycle Management
Launch is not a one-time event; it is the beginning of a commercial lifecycle that requires ongoing management. After the initial launch year, the commercial organization needs to transition from launch mode to lifecycle management mode. The CEO’s role in this transition is to endorse it and ensure the commercial organization has the strategy and resources for long-term commercial success.
The CCO leads the transition from launch to lifecycle management. The CEO receives regular commercial performance updates through the monthly dashboard and conducts a detailed annual strategic review of each major product’s commercial trajectory. Between these formal touchpoints, commercial lifecycle management is the CCO’s domain.
According to McKinsey analysis of pharmaceutical commercial lifecycle management, companies that invest in structured lifecycle management processes after launch significantly outperform those that treat launch as the end of the commercial investment cycle. The delegation structure that makes this possible is one where the commercial team has clear authority and sustained executive backing for post-launch commercial work.
For guidance on how supply chain delegation supports launch excellence, see pharma supply chain, which covers how pharma CEOs can ensure supply chain readiness for launch without operational involvement in supply chain management.
Building launch excellence through effective delegation is ultimately about building organizational capability: a commercial organization that knows how to launch products, a governance structure that coordinates cross-functional work effectively, and a CEO who provides strategic direction and executive backing without substituting for the commercial expertise that drives launch success.
Related Reading
For further context, explore Delegation Guide for Affordable Housing Nonprofit CEOs and Delegation Guide for Automotive CEO: Brand Management.